Efficacy of Intra-articular Ketorolac with Corticosteroid versus Corticosteroid Injection Alone In Adhesive Capsulitis of the Shoulder: A Triple blind randomized controlled trial

Efficacy of Intra-articular Ketorolac with Corticosteroid versus Corticosteroid Injection Alone In Adhe-sive Capsulitis of the Shoulder: A Triple blind randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240417004

Enrollment

Registered

2024-04-17

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive capsulitis is common disease manifesting with pain and limit motion of affected shoulder, inflammatory reaction as the main factor produce this symptom and progression of Adhesive capsulitis, intra-articular corticosteroid injection have a main stay in the non-operative treatment decrease pain maximum in 6 week and duration of drug no longer than 16 weeks after injection, Ketorolac in NASIDs considered as alternative in intra-articular injection it strong anti-infla

Interventions

Patient with shoulder adhesive capsulitis treatment by intra-articular ketorolac with corticosteroid injection ,Patient with shoulder adhesive capsulitis treatment by intra-articular corticosteroid

Experimental Drug,Experimental Drug

Intervention group ,control group

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adhesive capsulitis stage 1 (Freezing) and stage 2 (Frozen) Shoulder pain and indication for intra-articular injection Age 18-65 years

Exclusion criteria

Exclusion criteria: Concomitant massive rotator cuff tendinopathy Concomitant abnormal X-ray : GH OA, neoplasm Pain related to AC joint pathology History of pre-existing shoulder pathological : infection, trauma pregnancy Neurological disorder : CSR or stroke Drug allergy or contraindication : ketorolac, ASA, NSAIDs, TA, lidocaine Underling disease : Rheumatoid arthritis, on warfarin

Design outcomes

Primary

Measure	Time frame
Shoulder pain at 4 weeks, 12 weeks and 24 weeks end of after intervention Visual analog scale (0-10)	—

Secondary

Measure	Time frame
Shoulder pain and disability index score at 4 weeks, 12 weeks and 24 weeks end of after intervention Thai-version- SPADI score (0-100%),Range of motion shoulder at 4 weeks, 12 weeks and 24 weeks end of after intervention Degree of motion,Complication at 4 weeks, 12 weeks and 24 weeks end of after intervention Yes or No	—

Countries

Thailand

Contacts

Public ContactWUTTICHAI CHARIN

Lerdsin hospital

charin.pliw@gmail.com0635138884

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026